包头医学院学报
包頭醫學院學報
포두의학원학보
Journal of Baotou Medical College
2015年
9期
9-10
,共2页
胸腺五肽%紫杉醇%顺铂%化疗%非小细胞肺癌
胸腺五肽%紫杉醇%順鉑%化療%非小細胞肺癌
흉선오태%자삼순%순박%화료%비소세포폐암
Thymopentin%Paclitaxel%Cisplatin%Chemotherapy%Non-small cell lung cancer
目的:评价胸腺五肽联合化疗对晚期非小细胞肺癌的效果. 方法:64例晚期肺癌患者随机分为两组,观察组:TP方案加胸腺五肽.第1 d给予紫杉醇135 mg/m2加5%葡萄糖注射液或0.9%生理盐水500 mL,静滴3 h;第1~3 d给予顺铂30 mg/m2加0.9%生理盐水250 mL静滴;第1~14 d给予胸腺五肽1 mg加0.9%生理盐水250 mL静滴. 对照组:单纯TP方案化疗,方法同上. 3个化疗周期后观察患者近期疗效、血常规指标及不良反应情况. 结果:两组近期疗效比较差异无统计学意义;化疗后观察组白细胞总数明显高于对照组,差异有统计学意义(P <0.05);化疗前后两组血红蛋白与血小板计数差异无统计学意义;观察组不良反应发生率明显低于对照组,差异有统计学意义( P <0.05). 结论:胸腺五肽联合紫杉醇加顺铂化疗能提高晚期肺癌患者免疫功能,减少不良反应,提高生活质量,提高患者治疗依从性.
目的:評價胸腺五肽聯閤化療對晚期非小細胞肺癌的效果. 方法:64例晚期肺癌患者隨機分為兩組,觀察組:TP方案加胸腺五肽.第1 d給予紫杉醇135 mg/m2加5%葡萄糖註射液或0.9%生理鹽水500 mL,靜滴3 h;第1~3 d給予順鉑30 mg/m2加0.9%生理鹽水250 mL靜滴;第1~14 d給予胸腺五肽1 mg加0.9%生理鹽水250 mL靜滴. 對照組:單純TP方案化療,方法同上. 3箇化療週期後觀察患者近期療效、血常規指標及不良反應情況. 結果:兩組近期療效比較差異無統計學意義;化療後觀察組白細胞總數明顯高于對照組,差異有統計學意義(P <0.05);化療前後兩組血紅蛋白與血小闆計數差異無統計學意義;觀察組不良反應髮生率明顯低于對照組,差異有統計學意義( P <0.05). 結論:胸腺五肽聯閤紫杉醇加順鉑化療能提高晚期肺癌患者免疫功能,減少不良反應,提高生活質量,提高患者治療依從性.
목적:평개흉선오태연합화료대만기비소세포폐암적효과. 방법:64례만기폐암환자수궤분위량조,관찰조:TP방안가흉선오태.제1 d급여자삼순135 mg/m2가5%포도당주사액혹0.9%생리염수500 mL,정적3 h;제1~3 d급여순박30 mg/m2가0.9%생리염수250 mL정적;제1~14 d급여흉선오태1 mg가0.9%생리염수250 mL정적. 대조조:단순TP방안화료,방법동상. 3개화료주기후관찰환자근기료효、혈상규지표급불량반응정황. 결과:량조근기료효비교차이무통계학의의;화료후관찰조백세포총수명현고우대조조,차이유통계학의의(P <0.05);화료전후량조혈홍단백여혈소판계수차이무통계학의의;관찰조불량반응발생솔명현저우대조조,차이유통계학의의( P <0.05). 결론:흉선오태연합자삼순가순박화료능제고만기폐암환자면역공능,감소불량반응,제고생활질량,제고환자치료의종성.
Objective:To observe the effect of the combined use of thymopentin and paclitaxel and cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Methods:64 patients with advanced NSCLC were randomized into two groups, the treatment group and the control group.The former received paclitaxel 135 mg/m2 in glucose injection (5 %) or normal saline (0.9 %) 500 mL IV d1, cis-platin 30 mg/m2 in normal saline (0.9 %) 250 mL IV d1~d3, and thymopentin 1mg in normal saline (0.9%) 250 mL IV d1~d14.The latter was given the same therapy but thymopentin.The short-term effect, blood routine index and adverse reaction of all cases after 3 cycles of chemo-therapy were observed.Results:There were no statistically significant differences in the short -term curative effect between the treatment group and the control group.Leukocyte count in the treatment group was higher than that in the control group after chemotherapy , with difference significant ( P <0.05).There was no difference in hemoglobin and blood platelet count between the two groups before and after chemotherapy.The inci-dence of adverse reaction in the treatment group was significantly lower than that in the control group( P <0.05).Conclusion:The combined use of thymopentin and paclitaxel and cisplatin chemotherapy can increase the immunologic function of patients with advanced NSCLC , reducing the in-cidence rate of adverse effects, enhancing patients'quality of life and improving their treatment compliance.
